Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Eitemau Tebyg

• Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
  gan: Qian Jiang, et al.
  Cyhoeddwyd: (2022-10-01)
• Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
  gan: Qian Jiang, et al.
  Cyhoeddwyd: (2023-02-01)
• Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers
  gan: Hengbang Wang, et al.
  Cyhoeddwyd: (2024-09-01)
• Olverembatinib (HQP1351)-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in blast phase: results from a real-world study
  gan: Ziyu Wen, et al.
  Cyhoeddwyd: (2025-05-01)
• A nomogram for predicting T315I-free survival in chronic phase chronic myeloid leukemia patients: a multicenter retrospective study
  gan: Shi-wei Hu, et al.
  Cyhoeddwyd: (2025-02-01)